Listen to "Reality Check with Ben Swann" on Spreaker.

Goldman Sachs Questions Whether Curing Disease is Economically Sustainable

Must Read

New CDC Study: 70% Always Masked Contracted Covid, VS 3% Non-Masked

A new CDC study finds that 70% of those who ALWAYS wore a mask contracted C0VlD 14 days after...

President Trump: “Total Declassification” of Any/All Documents Related To Russia Investigation

Handwritten notes from former CIA Director John Brennan prove that the Trump/Russia connection appears to have been approved first...

Media Blackout of Third Option For President on Every Ballot in the U.S.

Our exclusive one on one interview with Libertarian Presidential Candidate Jo Jorgensen about the media blackout that is keeping...
Jay Syrmopoulos
Jay Syrmopoulos is a geopolitical analyst, freethinker, and ardent opponent of authoritarianism. He is currently a graduate student at the University of Denver pursuing a masters in Global Affairs and holds a BA in International Relations. Jay's writing has been featured on both mainstream and independent media - and has been viewed tens of millions of times.

New York, NY— Goldman Sachs, in an April report to clients, addressed an ethical conundrum facing pharmaceutical and biotechnology companies in regard to futuristic cures based on cutting edge gene therapy: “one shot cures,” rather than the model of continuous treatment, could be difficult for some “medicine developers looking for a sustained cash flow.”

In a report entitled “The Genome Revolution” Goldman Sachs analyst Salveen Richter asked, “Is curing patients a sustainable business model?”

“The potential to deliver ‘one shot cures’ is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies,” analyst Salveen Richter wrote in the note to clients on April 10. “While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.”

- Newsletter -

Richter highlighted the case of Gilead Sciences’ treatments for hepatitis C, which reportedly achieved cure rates of over 90 percent, as a cautionary tale.

“GILD is a case in point, where the success of its hepatitis C franchise has gradually exhausted the available pool of treatable patients,” the Goldman Sachs analyst wrote. “In the case of infectious diseases such as hepatitis C, curing existing patients also decreases the number of carriers able to transmit the virus to new patients, thus the incident pool also declines … Where an incident pool remains stable (eg, in cancer) the potential for a cure poses less risk to the sustainability of a franchise.”

CNBC reported that in 2015 the company’s U.S. sales for hepatitis C treatments peaked at $12.5 billion but have fallen each following year. Goldman has estimated that U.S. sales of these treatments in 2018 will be under $4 billion, according to the report.

The report proposed three possible solutions for biotech companies:

“Solution 1: Address large markets: Hemophilia is a $9-10bn WW market (hemophilia A, B), growing at ~6-7% annually.”

“Solution 2: Address disorders with high incidence: Spinal muscular atrophy (SMA) affects the cells (neurons) in the spinal cord, impacting the ability to walk, eat, or breathe.”

“Solution 3: Constant innovation and portfolio expansion: There are hundreds of inherited retinal diseases (genetics forms of blindness) … Pace of innovation will also play a role as future programs can offset the declining revenue trajectory of prior assets.”

The issues addressed in the report essentially means that mega-profits will be reduced to extremely large profits— but for more rare diseases, however, there is a concern that due to reduced potential income there may not be enough profits for biotech firms to justify the cost of research and clinical trials, usually at the cost of at least $1 billion.

- Advertisement -

Featrued Sponsors

Unstoppable Domains

Uncensorable blockchain domains. Every domain purchase supports Ben Swann and Truth in Media

Holland Center

Holland Center is a day treatment program and medical clinic for children with autism.

Pure VPN

Military grade privacy on all devices.
- Advertisement -

Latest News

video

New CDC Study: 70% Always Masked Contracted Covid, VS 3% Non-Masked

A new CDC study finds that 70% of those who ALWAYS wore a mask contracted C0VlD 14 days after...
video

President Trump: “Total Declassification” of Any/All Documents Related To Russia Investigation

Handwritten notes from former CIA Director John Brennan prove that the Trump/Russia connection appears to have been approved first by the Hillary Clinton campaign...
video

Media Blackout of Third Option For President on Every Ballot in the U.S.

Our exclusive one on one interview with Libertarian Presidential Candidate Jo Jorgensen about the media blackout that is keeping her out of the polls...
video

Exclusive Interview: Kyle Rittenhouse Unfairly Smeared by Facebook and MSM?

I interview the attorney for Kyle Rittenhouse about the new video which claims to prove that the 17 year-old acted in self-defense during the...
video

“Massachusetts Destroys Ballots”: Exclusive Interview With Senate Write-in Candidate Dr. Shiva

Breaking news in the race for U.S. Senate in Massachusetts as write-in candidate Dr. Shiva has established that the Massachusetts Secretary of State's Office...
- Advertisement -

More Articles Like This